- $4.68bn
- $4.57bn
- $493.63m
Brief: Inari Medical Says First Patient Enrolled In The DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes Of ClotTriever System In Deep Vein Thrombosis
U.S. RESEARCH ROUNDUP- Exxon Mobil, Netflix, Salesforce
Inari Medical jumps on upbeat preliminary Q4 revenue
Brief: Inari Medical Announces Preliminary 2022 Revenue And 2023 Guidance
Brief: Inari Medical - On Dec 16, 2022, Co And Units Entered Into An Amendment To The Loan, Guaranty And Security Agreement, Dated As Of September 4, 2020
Inari Medical Inc reports results for the quarter ended in September - Earnings Summary
Brief: Inari Medical Reports Third Quarter 2022 Financial Results
Inari Medical Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Inari Medical Announces In-Hospital And 30-Day Outcomes From The Fully Enrolled Clout Registry And Results From Propensity-Score Matched Comparison Of Clout Versus. Attract
Brief: Inari Medical Announces Results From Fully Enrolled 800-Patient US Cohort Of FlowTriever Flash Registry
U.S. RESEARCH ROUNDUP-Activision Blizzard, Inari Medical, Rent the Runway
Brief: Inari Medical Announces Three New Data Sets To Be Presented During Late-Breaking Clinical Trial Sessions At The 2022 TCT And VEINS Conferences
Brief: Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes Of The ClotTriever® System In Deep Vein Thrombosis
Brief: Inari Medical Reports Second Quarter 2022 Financial Results
Brief: Inari Medical COO Drew Hykes To Succeed Bill Hoffman As CEO, Effective Jan 1
Recession fears, high inflation threaten profit outlook for Medtech- BTIG
Inari Medical rises after Piper Sandler starts coverage with 'overweight'
Brief: Inari Medical Reports First Quarter 2022 Financial Results
Inari Medical Inc reports results for the quarter ended in March - Earnings Summary